KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $104.6 million.

  • Regeneron Pharmaceuticals' Shares Outstanding (Weighted Average) fell 305.84% to $104.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $104.6 million, marking a year-over-year decrease of 305.84%. This contributed to the annual value of $104.6 million for FY2025, which is 305.84% down from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Shares Outstanding (Weighted Average) of $104.6 million as of Q4 2025, which was down 305.84% from $105.1 million recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $108.1 million during Q2 2024, and its lowest value of $104.6 million during Q4 2025.
  • Over the past 5 years, Regeneron Pharmaceuticals' median Shares Outstanding (Weighted Average) value was $106.8 million (recorded in 2022), while the average stood at $106.7 million.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Shares Outstanding (Weighted Average) tumbled by 410.21% in 2021, and later soared by 256.65% in 2022.
  • Regeneron Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $105.7 million in 2021, then rose by 1.32% to $107.1 million in 2022, then decreased by 0.37% to $106.7 million in 2023, then increased by 1.12% to $107.9 million in 2024, then fell by 3.06% to $104.6 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $104.6 million in Q4 2025, compared to $105.1 million in Q3 2025 and $105.9 million in Q2 2025.